Skip to main content

Table 2 ACEI, angiotensin converter enzyme inhibitor; AKI, acute kidney injury; BSI, bloodstream infection; CMS, colistin methanesulfate; CVC, central venous catheter; NAs, other nephrotoxic antibiotics (aminoglycosides, glycopeptides); NSAID, nonsteroidal anti-inflammatory drug; SAPS II, Simplified Acute Physiology Score Two (calculated 24 h after ICU admission); VAP, ventilator-associated pneumonia.

From: Risk factors for acute kidney injury in critically ill patients receiving high intravenous doses of colistin methanesulfonate and/or other nephrotoxic antibiotics: a retrospective cohort study

Variables

Total cohort

(n = 79)

No AKI

(n = 168)

AKI

(n = 111)

P-value a

Age, years b

61 (43 to 74)

58 (39 to 71)

66 (51 to 77)

<0.01 *

Female, n (%)

92 (33)

62 (37)

30 (27)

0.09 **

SAPS II score b

44 (32 to 54)

38 (29 to 49)

50 (41 to 56)

<0.01 *

Septic shock at infection onset - n (%)

128 (46)

46 (27)

82 (74)

<0.01 **

Albumin serum levels <2 g/dL n (%)

38 (14)

15 (9)

23 (21)

<0.01 **

Total bilirubin serum levels >5 mg/dL n(%)

19 (7)

8 (5)

11 (10)

0.15 **

NSAID n (%)

70 (25)

48 (28)

22 (20)

0.13 **

ACEI n (%)

34 (12)

16 (10)

18 (16)

0.13 **

Immunocompromised pts n (%)

59 (21)

34 (20)

25 (23)

0.75 **

i.v. iodate contrast n (%)

94 (34)

53 (32)

41 (37)

0.42 **

Reason for ICU admission

    

Sepsis, n (%)

117 (42)

60 (36)

57 (51)

0.01 **

Neurological disease, n (%)

24 (8)

18 (10)

6 (5)

0.18 **

Trauma, n (%)

83 (30)

62 (37)

21 (19)

<0.01 **

Cardiovascular disease, n (%)

55 (20)

28 (17)

27 (24)

0.15 **

Comorbidity

    

Hypertension, n (%)

54 (20)

27 (16)

27 (24)

0.12**

Diabetes mellitus, (%)

13 (4)

6 (4)

7 (6)

0.44**

Congestive heart failure, n (%)

15 (6)

9 (5)

6 (5)

0.79 **

Two or more comorbidities

25 (9)

11 (6)

14 (13)

0.13 **

Type of infection

    

VAP, n (%)

200 (72)

118 (70)

82 (74)

0.6 **

CVC related-BSI, n (%)

62 (23)

39 (23)

23 (21)

0.73 **

Other, n (%)

17 (5)

11 (7)c

6 (5) d

0.89 **

Treatment

    

CMS, n (%)

90 (32)

59 (35)

31 (28)

0.25**

CMS+NAs, n (%)

57 (20)

31 (18)

26 (23)

0.39 **

CMS+ glycopeptides alone e, n (%)

39 (68)

23 (59)

16 (41)

1***

CMS + aminoglicoside alonee, n (%)

8 (14)

5 (62.5)

3 (37.5)

 

NAs, n (%)

132 (47)

78 (47)

54 (48)

0.8 **

Outcome

    

Days in ICU b

23 (13 to 37)

22 (13 to 34)

25 (14 to 42)

0.16 *

ICU mortality - n (%)

116 (41)

38 (23)

78 (70)

<0.01 **

  1. a Differences between subgroups with and without AKI onset after ICU admission: *Mann-Whitney test; **Chi-squared test, *** Fisher's exact test
  2. b Values are given as the median (interquartile range).
  3. c wound infection n = 2, abdominal abscess n = 5, urinary tract infection n = 2, meningitis n = 2
  4. d wound infection n = 1, abdominal abscess n = 3, urinary tract infection n = 2
  5. e in this analysis were excluded the patients who received aminoglycoside + glycopeptide ( n = 10) (18%)
Back to article page

Critical Care

ISSN: 1364-8535